Home About Services Drug Discovery News Careers Contact 20+ years of experience. PsychoGenics has built a vibrant contract research business based on high-capacity and high-quality testing with fast turnaround and delivery of results. Since our founding in 1999 we have performed tens of thousands of studies for hundreds of clients averaging 350 studies per year. Over 90 percent of our clients return for repeat business, attesting to the quality of service provided. Through our journey, our team of talented scientists have developed innovative AI-driven drug discovery platforms and analytical tools leading to shared-risk partnerships and numerous drug candidates in clinical trials. Our fee-for-service and partnered research have contributed to improved and needed treatments for patients suffering from severely disabling neuropsychiatric disorders. Management Team | Board Of Directors | Scientific Advisory Board Management Team Emer Leahy, Ph.D. President and CEO Read bio Mark Varney, Ph.D. Chief Scientific Officer Read bio Dani Brunner, Ph.D. Chief Innovation Officer Read bio Taleen Hanania, Ph.D. EVP, External Client Affairs Read bio Sylvie Ramboz, Ph.D. Sr. VP, Behavioral Pharmacology Read bio Afshin Ghavami, Ph.D. VP, Research Operations Read bio Steven C. Leiser, Ph.D. Sr. Director, Translational EEG Read bio Leslie Street, Ph.D. VP, Medicinal Chemistry Read bio Mukesh Bansal, Ph.D. VP, Data Science Read bio Christina Leahy VP, QA and Regulatory Affairs Read bio Mitchell Silverstein VP, Facilities and Operations Read bio Ronald E.D. Christopher VP, Finance Read bio Cindy Hsu, J.D. General Counsel Read bio Board Of Directors Henry Jarecki, M.D. Chairman Read bio Steve Bunney, M.D. Read bio George McLaughlin, M.B.A. Read bio Daniel Goodman, M.D., M.B.A. Read bio Emer Leahy, Ph.D. President and CEO Read bio Dayna Steele Read bio Scientific Advisory Board Eric Nestler, M.D., Ph.D. Read bio Maurizio Fava, M.D. Read bio John McCall, Ph.D. Read bio Rene Hen, Ph.D. Read bio John Krystal, Ph.D. Read bio Corporate Social Responsibility At PsychoGenics, we are pioneering new approaches to CNS drug discovery. Together with our partners and clients, we are committed to making a difference for patients, our employees, the environment and the communities where we live and work. The foundation for these commitments is reflected in our approach to corporate social responsibility (CSR). PsychoGenics is committed to collaborating with academia, government institutions, companies, and foundations, big and small, to help discover new treatments. Our focus on neuroscience, our deep scientific expertise, and our innovative approach to drug discovery has resulted in several novel treatments in clinical trials with potential to transform the lives of patients suffering from disabling neuropsychiatric disorders. Our employees care deeply and believe in the work we do, knowing that we can make a meaningful difference in patients’ lives. We have built a diverse and inclusive culture where individuals bring a broad range of capabilities, experiences, and perspectives and are encouraged to collaborate, lead, and grow. We reward hard work and creativity and we encourage our employees to take the initiative and seek out growth opportunities. PsychoGenics is committed to minimizing the environmental effect of its operations through the promotion of environmental awareness and use of online communications and teleconferencing tools, as well as running an energy-efficient LEED-certified building and practicing sustainable waste management. We also identify and assess our environmental impacts on an ongoing basis. Want to get in touch? Connect with the PsychoGenics research team. Connect With Us CONTACT PsychoGenics Inc. 215 College Road, Paramus, NJ 07652 Email: info@psychogenics.com Phone: (914) 406-8019 Fax: (914) 406-8090 Privacy Policy Terms of Use Financial Conflict of Interest Policy Copyright ©2021 PsychoGenics Inc. All rights reserved.